mobile-logo

Author: Peter Sargent

05 Feb

Contract Award

by Peter Sargent
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client, Numab Therapeutics (“Numab”). The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in support of one of Numab’s oncology assets entering the clinic and will help inform dose and scheduling decisions.     Dr...

Read More
18 Oct

Conference Attendance Announcement – BioEurope 2023

by Peter Sargent
in Events
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending Europe’s Flagship Partnering Event for the Life Sciences Industry, BioEurope 2023 in Munich, Germany on November 6-8th.   Physiomics’ Chief Operating Officer, Dr Pete Sargent and Head of Business Development, Hayley Close will be attending the event. The aim is to engage with leaders from across...

Read More
04 Oct

Change of Registered Office

by Peter Sargent
in Investor News / RNS, Other News
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, announces that, effective today, its registered office has changed to Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (Broker) Claire Louise Noyce +44 (0) 203 764 2341   Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20 7409 3494       Notes to Editor    About Physiomics Physiomics plc combines cutting...

Read More